Form 4: VolitionRx CCO Gael Forterre Awarded 149,000 RSUs

VolitionRx's Chief Commercial Officer, Gael Forterre, was awarded 149,000 restricted stock units as part of the company's 2024 Stock Incentive Plan, in lieu of cash compensation.

Summary

• Gael Forterre, Chief Commercial Officer of VolitionRx Ltd (VNRX), was awarded 149,000 restricted stock units (RSUs).
• The RSUs were granted on February 26, 2026, under the Issuer's 2024 Stock Incentive Plan.
• This award is in lieu of cash compensation that would otherwise have been owed to Mr. Forterre.
• The RSUs will be earned in twelve approximately equal monthly installments starting March 1, 2026.
• They are subject to additional time-based vesting in a single installment on February 26, 2027.
• Vesting is generally contingent on continued service by Mr. Forterre.
• Upon vesting and settlement, Mr. Forterre will receive common stock shares equal to the vested RSUs.
• Following this transaction, Mr. Forterre directly beneficially owns 338,872 shares of common stock.
• He also indirectly beneficially owns 5,000 shares through his spouse and 32,500 shares through Armorica Partners, LLC, where he is the managing director and sole shareholder.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns the Chief Commercial Officer's interests with long-term shareholder value and conserves cash, which is generally favorable for growth-stage companies.

Positives

• Award of 149,000 Restricted Stock Units (RSUs) to the Chief Commercial Officer aligns management's interests with shareholders.
• The RSUs are granted in lieu of cash compensation, potentially conserving company cash.

Risks

• Vesting of RSUs is subject to continued service, meaning the full benefit is contingent on Mr. Forterre remaining with the company.

Future Outlook

The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026, and will remain subject to additional time-based vesting in a single installment on February 26, 2027, contingent on continued service.

Management Comments

• "The reporting person was awarded 149,000 restricted stock units ('RSUs') under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person."

Industry Context

StockSavvy.ai notes that executive compensation through equity awards like RSUs is a common practice in the biotechnology and diagnostics industry, aligning executive incentives with long-term shareholder value. This move by VolitionRx is consistent with broader industry trends to conserve cash while retaining and incentivizing key talent.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice across the biotechnology and diagnostics sector, similar to companies like Exact Sciences (EXAS) or Guardant Health (GH) which frequently utilize equity awards to incentivize leadership.
• The structure of vesting over time, contingent on continued service, is also a common mechanism to promote long-term commitment and performance, mirroring practices seen in compensation packages for executives at peer companies.

Related Party Transactions

• Gael Forterre, as managing director and sole shareholder of Armorica Partners, LLC, has voting and dispositive control over 32,500 shares held by Armorica Partners. He disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance and conservation of cash.
• Management (Gael Forterre): Receives significant equity compensation, incentivizing continued service and performance.

Next Steps

• RSUs will begin earning in twelve approximately equal monthly installments starting March 1, 2026.
• Additional time-based vesting for RSUs will occur on February 26, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation award to a key executive, which is a standard practice for aligning management incentives with shareholder interests. It does not present new information that would significantly alter the company's fundamental outlook or warrant a change in investment recommendation beyond a 'hold' position, assuming the investor's existing thesis remains intact.

Keywords

VolitionRx, VNRX, Gael Forterre, Restricted Stock Units, RSUs, Insider Trading, SEC Form 4, Executive Compensation, Stock Incentive Plan, Chief Commercial Officer